-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Zenas BioPharma, Raises Price Target to $40

Benzinga·10/09/2025 13:07:51
Listen to the news
Wedbush analyst Martin Fan maintains Zenas BioPharma (NASDAQ:ZBIO) with a Outperform and raises the price target from $35 to $40.